Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人:
申请号：
EP18170999.9
公开号：
EP3566718A1
申请日:
2018.05.07
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present disclosure relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg) -depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals.
